Cure Network Ventures

Cure Network Ventures is a wholly owned, for-profit subsidiary of Gladstone Institutes created in 2015 to help translate Gladstone biomedical discoveries into commercial opportunities. The organization facilitates relationships among Gladstone scientists, investors, contract research organizations, and established biopharmaceutical companies, and it appears to function primarily as a venture creation and translational commercialization vehicle rather than as a standalone drug developer. Its best-documented activity is the formation of Cure Network Dolby Acceleration Partners, a joint effort focused on developing novel small-molecule therapeutics for Alzheimer's disease and related neurological disorders. Publicly available information indicates a preclinical focus centered on tau-lowering approaches emerging from Gladstone research.